Liposomal amphotericin B as a treatment for human leishmaniasis

Bibliography

• WHO. Control of the Leishmaniasis. Report of a meeting of the WHO expert committee on the control of Leishmaniasis; 22 – 26 March 2010; Geneva
   Google Scholar
• Alvar J, Velez ID, Bern C, Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012;7(5):e35671
   PubMed Web of Science ®Google Scholar
• Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001;6(11):849-54
   PubMed Web of Science ®Google Scholar
• Musa A, Khalil E, Hailu A, Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl Trop Dis 2012;6(6):e1674
   PubMed Web of Science ®Google Scholar
• Sundar S, Sinha PK, Rai M, Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 2011;377(9764):477-86
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010;362(6):504-12
   PubMed Web of Science ®Google Scholar
• Rijal S, Chappuis F, Singh R, Sodium stibogluconate cardiotoxicity and safety of generics. Trans R Soc Trop Med Hyg 2003;97(5):597-8
   PubMed Web of Science ®Google Scholar
• Sundar S, Singh A, Rai M, Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 2012;55(4):543-50
   PubMed Web of Science ®Google Scholar
• Hailu A, Musa A, Wasunna M, Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis 2010;4(10):e709
   PubMed Web of Science ®Google Scholar
• http://www.dndi.org/diseases/vl.html
   Google Scholar
• DNDi. Target Product Profile. Available from: http://dndi.org/diseases/vl/target-product-profile.html
   Google Scholar
• Berman JD, Badaro R, Thakur CP, Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 1998;76(1):25-32
   PubMed Web of Science ®Google Scholar
• Bodhe PV, Kotwani RN, Kirodian BG, Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1999;93(3):314-18
   PubMed Web of Science ®Google Scholar
• Cascio A, di Martino L, Occorsio P, A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience. J Antimicrob Chemother 2004;54(1):217-20
   PubMed Web of Science ®Google Scholar
• Davidson RN, di Martino L, Gradoni L, Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996;22(6):938-43
   PubMed Web of Science ®Google Scholar
• Davidson RN, Di Martino L, Gradoni L, Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994;87(2):75-81
   PubMedGoogle Scholar
• di Martino L, Davidson RN, Giacchino R, Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J Pediatr 1997;131(2):271-7
   PubMed Web of Science ®Google Scholar
• Kafetzis DA, Velissariou IM, Stabouli S, Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds? Int J Antimicrob Agents 2005;25(1):26-30
   PubMed Web of Science ®Google Scholar
• Molina I, Falco V, Crespo M, Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2007;60(4):837-42
   PubMed Web of Science ®Google Scholar
• Mondal S, Bhattacharya P, Rahaman M, A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy. PLoS Negl Trop Med 2010;4(7):e764
   Google Scholar
• Mueller M, Balasegaram M, Koummuki Y, A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother 2006;58(4):811-15
   PubMed Web of Science ®Google Scholar
• Mueller M, Ritmeijer K, Balasegaram M, Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg 2007;101(1):19-24
   PubMed Web of Science ®Google Scholar
• Pagliano P, Rossi M, Rescigno C, Mediterranean visceral leishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995-2001). J Antimicrob Chemother 2003;52(2):264-8
   PubMed Web of Science ®Google Scholar
• Ritmeijer K, ter Horst R, Chane S, et al. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 2011;53(12):e152-8
   PubMed Web of Science ®Google Scholar
• Sanath SS, Gogtay NJ, Kshirsagar NA. Post-marketing study to assess the safety, tolerability and effectiveness of Fungisome: an Indian liposomal amphotericin B preparation. J Postgrad Med 2005;51(Suppl 1):S58-63
   PubMedGoogle Scholar
• Seaman J, Boer C, Wilkinson R, Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995;21(1):188-93
   PubMed Web of Science ®Google Scholar
• Sinha PK, Roddy P, Palma PP, Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg 2010;83(2):357-64
   PubMed Web of Science ®Google Scholar
• Sinha PK, van Griensven J, Pandey K, Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 2011;53(7):e91-8
   PubMed Web of Science ®Google Scholar
• Sundar S, Agrawal G, Rai M, Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001;323(7310):419-22
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003;37(6):800-4
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002;66(2):143-6
   PubMed Web of Science ®Google Scholar
• Sundar S, Mehta H, Suresh AV, Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004;38(3):377-83
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M, Chakravarty J, New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008;47(8):1000-6
   PubMed Web of Science ®Google Scholar
• Sundar S, Sinha PK, Verma DK, Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg 2011;105(2):115-17
   PubMed Web of Science ®Google Scholar
• Syriopoulou V, Daikos GL, Theodoridou M, Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 2003;36(5):560-6
   PubMed Web of Science ®Google Scholar
• Thakur CP. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 2001;17(1):67-70
   PubMed Web of Science ®Google Scholar
• Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S. Amphotericin B formulations and drug targeting. J Pharm Sci 2008;97(7):2405-25
   PubMed Web of Science ®Google Scholar
• Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002;49(Suppl 1):31-6
   PubMed Web of Science ®Google Scholar
• Approval letter. FDA. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/050740a_081797-1.pdf
   Google Scholar
• Berman JD. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999;28(1):49-51
   PubMed Web of Science ®Google Scholar
• Moon S, Jambert E, Childs M, von Schoen-Angerer T. A win-win solution?: a critical analysis of tiered pricing to improve access to medicines in developing countries. Global Health 2011;7(1):39
   PubMedGoogle Scholar
• Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01067443?term=ambisome+AND+miltefosine&rank=2
   Google Scholar
• Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil (LVBrasil). ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01310738?term=ambisome%2C+meglumine+antimoniate&rank=2
   Google Scholar
• Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With Visceral Leishmaniasis. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00832208?term=ambisome+AND+visceral+leishmaniasis&rank=10
   Google Scholar
• Lachaud L, Bourgeois N, Plourde M, Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis 2009;48(2):e16-22
   PubMed Web of Science ®Google Scholar
• Di Giorgio C, Faraut-Gambarelli F, Imbert A, Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis. J Antimicrob Chemother 1999;44(1):71-6
   PubMed Web of Science ®Google Scholar
• Purkait B, Kumar A, Nandi N, Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob Agents Chemother 2012;56(2):1031-41
   PubMed Web of Science ®Google Scholar
• Draft Guidance for Industry on Liposome Drug Products. US FDA. 2002. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070570.pdf
   Google Scholar
• Draft Guidance on Doxorubicin Hydrochloride. US FDA. 2010. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM199635.pdf
   Google Scholar
• Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. EMA. 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500109479.pdf
   Google Scholar
• Burgess DJ, Crommelin DJ, Hussain AS, Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report. AAPS PharmSci 2004;6(1):E11
   PubMedGoogle Scholar
• Burgess DJ, Hussain AS, Ingallinera TS, Chen ML. Assuring quality and performance of sustained and controlled release parenterals: workshop report. AAPS PharmSci 2002;4(2):E7
   PubMedGoogle Scholar
• Burgess P, Hutt PB, Farokhzad OC, On firm ground: IP protection of therapeutic nanoparticles. Nat Biotechnol 2010;28(12):1267-70
   PubMed Web of Science ®Google Scholar
• Lionberger RA. FDA critical path initiatives: opportunities for generic drug development. AAPS J 2008;10(1):103-9
   PubMed Web of Science ®Google Scholar
• Mamidi RN, Weng S, Stellar S, Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products? Cancer Chemother Pharmacol 2010;66(6):1173-84
   PubMed Web of Science ®Google Scholar
• Olson JA, Adler-Moore JP, Jensen GM, Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products. Antimicrob Agents Chemother 2008;52(1):259-68
   PubMed Web of Science ®Google Scholar
• Schellekens H, Klinger E, Muhlebach S, The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol 2011;59(1):176-83
   PubMed Web of Science ®Google Scholar
• British National Formulary. 2012. Available from: http://www.bnf.org/bnf/index.htm
   Google Scholar
• Registry of the South African Medicine Price. 2012. Available from: http://www.mpr.gov.za/PublishedDocuments.aspx#DocCatId=21
   Google Scholar
• Gilead, Annual Report 2011. Filed in February 2012. Available from: http://www.gilead.com/AR2011/GileadSciences_10K_20120223.pdf
   Google Scholar
• Approved draft labelling AmBisome. US FDA. 1997. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-740S001_AmBisome_prntlbl.pdf
   Google Scholar
• Collin S, Davidson R, Ritmeijer K, Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 2004;38(5):612-19
   PubMed Web of Science ®Google Scholar
• Chappuis F, Alirol E, Worku DT, High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B. Antimicrob Agents Chemother 2011;55(1):455-6
   PubMed Web of Science ®Google Scholar
• Gorski S, Collin SM, Ritmeijer K, Visceral leishmaniasis relapse in Southern Sudan (1999 – 2007): a retrospective study of risk factors and trends. PLoS Negl Trop Med 2010;4(6):e705
   Google Scholar
• Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 1996;124(7):664-72
   PubMed Web of Science ®Google Scholar
• Boelaert M, Meheus F, Sanchez A, The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. Trop Med Int Health 2009;14(6):639-44
   PubMed Web of Science ®Google Scholar
• Pascual Martinez F, Picado A, Roddy P, Palma P. Low castes have poor access to visceral leishmaniasis treatment in Bihar, India. Trop Med Int Health 2012;17(5):666-73
   PubMed Web of Science ®Google Scholar
• Meheus F, Balasegaram M, Olliaro P, Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Med 2010;4(9):e818
   Google Scholar
• Burki T. Drug donated for treatment of visceral leishmaniasis. Lancet Infect Dis 2012;12(2):106-7
   PubMedGoogle Scholar
• WHO. Technical Report Series (TRS), Annex 6 "Costs of medicines in current use for the treatment of leishmaniasis". 2010
   Google Scholar
• Reithinger R, Dujardin JC, Louzir H, Cutaneous leishmaniasis. Lancet Infect Dis 2007;7(9):581-96
   PubMed Web of Science ®Google Scholar
• Wortmann G, Zapor M, Ressner R, Liposomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2010;83(5):1028-33
   PubMed Web of Science ®Google Scholar
• Solomon M, Pavlotsky F, Leshem E, Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. JEADV 2011;25(8):973-7
   Google Scholar
• Solomon M, Pavlotsky F, Barzilai A, Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers. J Am Acad Dermatol 2012; In press
   PubMed Web of Science ®Google Scholar
• Motta JO, Sampaio RNR. A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2012;26:331-5
   PubMed Web of Science ®Google Scholar
• Amato VS, Tuon FF, Siqueira AM, Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg 2007;77(2):266-74
   PubMed Web of Science ®Google Scholar
• Sampaio RN, Marsden PD. Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B. Rev Soc Bras Med Trop 1997;30(2):125-8
   PubMedGoogle Scholar
• Amato VS, Tuon FF, Camargo RA, Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg 2011;85(5):818-19
   PubMed Web of Science ®Google Scholar
• Musa AM, Khalil EA, Mahgoub FA, Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol 2005;99(6):563-9
   PubMed Web of Science ®Google Scholar